1. Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations.
- Author
-
Dutra LA, Silva PVC, Ferreira JHF, Marques AC, Toso FF, Vasconcelos CCF, Brum DG, Pereira SLDA, Adoni T, Rocha LJA, Sampaio LPB, Sousa NAC, Paolilo RB, Pizzol AD, Costa BKD, Disserol CCD, Pupe C, Valle DAD, Diniz DS, Abrantes FF, Schmidt FDR, Cendes F, Oliveira FTM, Martins GJ, Silva GD, Lin K, Pinto LF, Santos MLSF, Gonçalves MVM, Krueger MB, Haziot MEJ, Barsottini OGP, Nascimento OJMD, Nóbrega PR, Proveti PM, Castilhos RMD, Daccach V, and Glehn FV
- Subjects
- Humans, Brazil, Child, Adult, Hashimoto Disease diagnosis, Hashimoto Disease therapy, Delphi Technique, Autoantibodies blood, Encephalitis diagnosis, Encephalitis therapy, Encephalitis immunology, Consensus
- Abstract
Background: Autoimmune encephalitis (AIE) is a group of inflammatory diseases characterized by the presence of antibodies against neuronal and glial antigens, leading to subacute psychiatric symptoms, memory complaints, and movement disorders. The patients are predominantly young, and delays in treatment are associated with worse prognosis., Objective: With the support of the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, ABN) and the Brazilian Society of Child Neurology (Sociedade Brasileira de Neurologia Infantil, SBNI), a consensus on the diagnosis and treatment of AIE in Brazil was developed using the Delphi method., Methods: A total of 25 panelists, including adult and child neurologists, participated in the study., Results: The panelists agreed that patients fulfilling criteria for possible AIE should be screened for antineuronal antibodies in the serum and cerebrospinal fluid (CSF) using the tissue-based assay (TBA) and cell-based assay (CBA) techniques. Children should also be screened for anti-myelin oligodendrocyte glucoprotein antibodies (anti-MOG). Treatment should be started within the first 4 weeks of symptoms. The first-line option is methylprednisolone plus intravenous immunoglobulin (IVIG) or plasmapheresis, the second-line includes rituximab and/or cyclophosphamide, while third-line treatment options are bortezomib and tocilizumab. Most seizures in AIE are symptomatic, and antiseizure medications may be weaned after the acute stage. In anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, the panelists have agreed that oral immunosuppressant agents should not be used. Patients should be evaluated at the acute and postacute stages using functional and cognitive scales, such as the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Modified Rankin Scale (mRS), and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE)., Conclusion: The present study provides tangible evidence for the effective management of AIE patients within the Brazilian healthcare system., Competing Interests: LAD reports that she has received a grant for the Brazilian Autoimmune Encephalitis Network (Rede Brasileira de Encefalites Autoimunes), from Laboratório Fleury., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF